Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

In both cardiovascular disease and cancer, there are established sex-based differences in
prevalence and outcomes. Males and females may also differ in terms of risk of cardiotoxicity …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

Immune checkpoint inhibitors (ICI) have transformed the therapeutic landscape in oncology.
However, ICI can induce uncommon life-threatening autoimmune T-cell-mediated …

BACKGROUND: Immune checkpoint inhibitors (ICIs) are approved for multiple cancers but
can result in ICI-associated myocarditis, an infrequent but life-threatening condition …

Background In addition to restoring anti-tumor immune responses, immune checkpoint
inhibitors (ICI) may also induce immune-related adverse events (irAE) that can affect any …

Immune-checkpoint inhibitors (ICIs) have revolutionized oncology, with nearly 50% of all
patients with cancer eligible for treatment with ICIs. However, patients on ICI therapy are at …

Immune-checkpoint inhibitors (ICI) have revolutionized cancer therapy but are associated
with infrequent but lethal myocarditis, for which management remains uncertain. Abatacept …

Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer
treatment but are associated with myocarditis. Here, we report that tumor-bearing mice …